Christian P. R. Hackenberger completed his graduate studies at the universities of Freiburg and UW Madison and his doctoral studies in 2003 at the RWTH Aachen. After a postdoctoral position at MIT with Barbara Imperiali, he started his own group at the Freie Universität Berlin in 2005 funded by the German Science Foundation in the Emmy Noether Program and the Boehringer-Ingelheim Foundation within the Plus 3 award. In 2012, he was appointed Leibniz-Humboldt Professor for Chemical Biology at the Leibniz-Research Institute for Molecular Pharmacology and the Humboldt Universität zu Berlin. His group works on the development of new chemoselective and bioorthogonal reactions for proteomic research and novel approaches to functional protein synthesis and delivery, in particular for the labeling and modification of different antibody formats. Since 2018, he is co-founder of the planned start-up 'Tubulis Technologies', a company that ventures into developing better tolerable cancer drugs based on protein- and antibody-drug conjugates.